Citadel Advisors’s NEOPHOTONICS CORP NPTN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-14,600
Closed -$127K 15318
2021
Q3
$127K Sell
14,600
-7,300
-33% -$66.6K ﹤0.01% 12582
2021
Q2
$224K Sell
21,900
-5,900
-21% -$62.3K ﹤0.01% 11921
2021
Q1
$332K Sell
27,800
-9,900
-26% -$112K ﹤0.01% 10606
2020
Q4
$343K Buy
37,700
+20,600
+120% +$159K ﹤0.01% 8840
2020
Q3
$104K Buy
17,100
+2,000
+13% +$15.3K ﹤0.01% 9256
2020
Q2
$134K Buy
+15,100
New +$130K ﹤0.01% 8819
2020
Q1
Sell
-32,700
Closed -$288K 10428
2019
Q4
$288K Buy
+32,700
New +$245K ﹤0.01% 7645
2019
Q3
Sell
-25,100
Closed -$105K 9976
2019
Q2
$105K Sell
25,100
-77,300
-75% -$408K ﹤0.01% 8518
2019
Q1
$644K Buy
102,400
+82,700
+420% +$579K ﹤0.01% 6364
2018
Q4
$128K Sell
19,700
-14,500
-42% -$111K ﹤0.01% 8139
2018
Q3
$284K Buy
+34,200
New +$260K ﹤0.01% 7659
2018
Q1
Sell
-10,800
Closed -$71K 8981
2017
Q4
$71K Sell
10,800
-3,200
-23% -$19.5K ﹤0.01% 7535
2017
Q3
$78K Sell
14,000
-500
-3% -$3.37K ﹤0.01% 7101
2017
Q2
$112K Sell
14,500
-2,900
-17% -$24.5K ﹤0.01% 6867
2017
Q1
$157K Buy
17,400
+1,800
+12% +$18.8K ﹤0.01% 6665
2016
Q4
$169K Sell
15,600
-2,400
-13% -$32K ﹤0.01% 6424
2016
Q3
$294K Buy
+18,000
New +$253K ﹤0.01% 5702
2016
Q1
Sell
-5,000
Closed -$54K 8356
2015
Q4
$54K Buy
5,000
+500
+11% +$4.52K ﹤0.01% 7252
2015
Q3
$31K Buy
4,500
+2,300
+105% +$17.8K ﹤0.01% 7902
2015
Q2
$20K Buy
+2,200
New +$16.7K ﹤0.01% 8156

Other funds holding NPTN

Citadel Advisors's NPTN Position: Q3 2022 in Review

Citadel Advisors sold out of NEOPHOTONICS CORP (NPTN) in Q3 2022, closing a stake of 260,595 shares — an estimated $4.1M sold.

Citadel Advisors first reported a position in NPTN in Q2 2014 and held it in 29 quarters. The position peaked at $6.88M in Q1 2016. 2 funds tracked by Wall St. Rank hold NPTN as of Q3 2022.

  • Citadel Advisors reported no remaining NEOPHOTONICS CORP position as of Q3 2022 after selling out during the quarter.
  • Citadel Advisors sold 260,595 NEOPHOTONICS CORP shares in Q3 2022, an estimated $4.1M.
  • Citadel Advisors first reported a position in NEOPHOTONICS CORP in Q2 2014 and held it in 29 quarters.
  • Citadel Advisors's NEOPHOTONICS CORP position peaked at $6.88M in Q1 2016.
  • 2 funds tracked by Wall St. Rank held NEOPHOTONICS CORP as of Q3 2022.

Based on Citadel Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.